The Role of Atypical Cannabinoid Ligands O-1602 and O-1918 on Skeletal Muscle Homeostasis with a Focus on Obesity

• Published in: International journal of molecular sciences 2020-08, Vol.21 (16), p.5922
• Main Authors: Simcocks, Anna C, O'Keefe, Lannie, Jenkin, Kayte A, Cornall, Lauren M, Grinfeld, Esther, Mathai, Michael L, Hryciw, Deanne H, McAinch, Andrew J
• Format: Article
• Language: English
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Adaptor Proteins, Signal Transducing - metabolism; Adiponectin; Adult; Animals; Anisoles - pharmacology; Atypical Cannabinoids; Body fat; Cannabidiol; Cannabidiol - analogs & derivatives; Cannabidiol - pharmacology; Cannabinoids; Cell Line; Cells, Cultured; Cyclohexanes - pharmacology; Diabetes; Energy; Energy balance; Fatty acids; Fatty Acids - metabolism; Female; Gene expression; GPR18; Homeostasis; Humans; Insulin resistance; Ligands; Male; Metabolism; Mice; Middle Aged; Morbidity; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Muscles; Musculoskeletal system; Myotubes; NFATC Transcription Factors - genetics; NFATC Transcription Factors - metabolism; O-1602; O-1918; Obesity; Obesity - metabolism; obesity and skeletal muscle; Oxidative metabolism; PPAR gamma - genetics; PPAR gamma - metabolism; Proteins; Pyruvate Dehydrogenase Acetyl-Transferring Kinase - genetics; Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled - genetics; Receptors, G-Protein-Coupled - metabolism; Rodents; Signal transduction; Skeletal muscle
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21165922

O-1602 and O-1918 are atypical cannabinoid ligands for GPR55 and GPR18, which may be novel pharmaceuticals for the treatment of obesity by targeting energy homeostasis regulation in skeletal muscle. This study aimed to determine the effect of O-1602 or O-1918 on markers of oxidative capacity and fatty acid metabolism in the skeletal muscle. Diet-induced obese (DIO) male Sprague Dawley rats were administered a daily intraperitoneal injection of O-1602, O-1918 or vehicle for 6 weeks. C C myotubes were treated with O-1602 or O-1918 and human primary myotubes were treated with O-1918. GPR18 mRNA was expressed in the skeletal muscle of DIO rats and was up-regulated in red gastrocnemius when compared with white gastrocnemius. O-1602 had no effect on mRNA expression on selected markers for oxidative capacity, fatty acid metabolism or adiponectin signalling in gastrocnemius from DIO rats or in C C myotubes, while APPL2 mRNA was up-regulated in white gastrocnemius in DIO rats treated with O-1918. In C C myotubes treated with O-1918, PGC1α, NFATc1 and PDK4 mRNA were up-regulated. There were no effects of O-1918 on mRNA expression in human primary myotubes derived from obese and obese T2DM individuals. In conclusion, O-1602 does not alter mRNA expression of key pathways important for skeletal muscle energy homeostasis in obesity. In contrast, O-1918 appears to alter markers of oxidative capacity and fatty acid metabolism in C C myotubes only. GPR18 is expressed in DIO rat skeletal muscle and future work could focus on selectively modulating GPR18 in a tissue-specific manner, which may be beneficial for obesity-targeted therapies.